Bernstein research firm maintained a positive outlook on Eli Lilly (NYSE:LLY) shares, reiterating an Outperform rating and a ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.18% to 44,795.97 while the NASDAQ fell 0.25% to 19,583.83. The S&P 500 also ...

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...

European shares were higher today. The eurozone's STOXX 600 rose 0.6%, Germany's DAX 40 gained 0.2% and France's CAC 40 ...

The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...